Kura Oncology Presents Preliminary Clinical and Preclinical Data for Tipifarnib in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma
Go back to Kura Oncology Presents Preliminary Clinical and Preclinical Data for Tipifarnib in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma| (NASDAQ: KURA) | Delayed: 10.36 +0.43 (4.33%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.93 | 52 Week High | $8.90 | |||
| Open | $9.96 | 52 Week Low | $2.50 | |||
| Day High | $10.54 | P/E | N/A | |||
| Day Low | $9.95 | EPS | $0.00 | |||
| Volume | 1,383,616 | |||||
